Unless there are some milestones booked, it looks like it will be a close call if Enanta generates a profit this quarter. That'll break a nice string.
Revenue Guidance
For the quarter ending March 31, 2016, which marks the beginning of a new year for the calculation of Enanta’s annually tiered royalties, Enanta expects its royalty revenue to be at least 3% percent of AbbVie’s reported VIEKIRA sales. The actual percentage will depend primarily on the amounts and portions of those sales that are 2-DAA or 3-DAA regimen sales. Under its agreement with AbbVie, Enanta is entitled to receive annually tiered, double-digit royalties on specified portions of sales that are allocated to paritaprevir using 30% of 3-DAA sales (VIEKIRA PAK™ or VIEKIRAX® + EXVIERA®) and 45% of 2-DAA sales (TECHNIVIE® or VIEKIRAX®) for the allocation.
